Skip to main content

Table 2 Demographic and clinical variables of MS patients and healthy controls (HC)

From: Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis

  MS
n=195
HC
n=60
Sex (M/F) 66/129 21/39
Age 43.1±11.3 39.9±8.5
Disease duration (months) 104.9+93.2 --
Age at onset 34.5+10.3 --
EDSS 2 (0-6.0) --
Disease subtype
CIS 24 --
RRMS 129 --
SPMS 6 --
PPMS 36 --
Treatments
DMD
  FNb 36 --
  GA 18 --
  NTZ 22 --
  FTY 20 --
Experimental drug
  EGCG 6 --
Untreated
  Untreated 93 --
  1. M male, F female, EDSS Expanded Disability Status Scale, CIS clinically isolated syndrome, RRMS relapsing-remitting MS, SPMS secondary-progressive MS, PPMS primary-progressive MS, DMD disease-modifying drug, IFNb interferon beta, GA glatiramer acetate, NTZ natalizumab, FTY fingolimod, EGCG epigallocatechin-gallate